Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual GIP/GLP-1 agonists (e.g., tirzepatide) induce significant weight loss and improve glycemic control by acting on multiple pathways including appetite suppression, delayed gastric emptying, and improved adipose tissue health.
GLP-1 agonists like semaglutide are FDA-approved for weight loss and diabetes. They work by mimicking gut hormones to reduce appetite and slow digestion. Clinical trials show significant weight loss (up to ~15% in some ranges) and improved blood sugar. They are typically taken once weekly.
StrongSupportsHIGH confidence
These drugs act by targeting various mechanisms involved in the pathophysiology of obesity and T2DM, and they have been shown to induce significant weight loss and improve glycemic control in obese individuals with T2DM.
Why this rating
Cites multiple clinical trials and FDA approvals.
Source
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi et al. · Molecules · 2023
narrative_reviewCited 60×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →